PROCEPT BioRobotics (PRCT) investor relations material

Market opportunity and patient needs

• BPH is significantly undertreated, with 400,000 surgical cases annually and 8 million men on medication; 1.1 million stop medication each year, and 40 million live with BPH.

• Patients prioritize symptom relief, preservation of urinary and sexual function, and avoiding repeat procedures.

• Existing therapies often compromise on these priorities, with high rates of incontinence and ED after radical prostatectomy and frequent retreatments for non-resective therapies.

Technology and clinical differentiation

• Aquablation uses water jet technology and AI mapping, offering low incontinence rates, preserved sexual function, and durability comparable to TURP.

• The procedure is fast, reliable, and avoids heat, radiation, or steam, aiming to set a new standard of care for BPH.

Financial performance and operational initiatives

• Revenue guidance for the year is $390M–$410M, with improving gross margins and rising ASPs for both systems and consumables.

• EBITDA loss is declining, with expectations to be EBITDA positive by Q4.

• Discounting practices have been eliminated, leading to higher handpiece and system pricing.

• A trade-in program for system upgrades has seen strong uptake, with 14 upgrades in Q2.